Направления и особенности формирования экспортного потенциала российских фармацевтических компаний (1142512), страница 39
Текст из файла (страница 39)
Javalgi, R.G. An empirical examination of factors influencing the internationalizationof service firms / R.G. Javalgi, D.A. Griffith, D.S. White // Journal of ServicesMarketing.– 2002. – № 17(2). – P. 246-262.166. Jun, L. Industrial clusters, shared resources and firm performance / L. Jun, G. Shuai //Entrepreneurship and Regional Development. – 2011.
– № 24(5-6). – P. 1-25.167. Kagochi, J.M. R&D investments, human capital, and the competitiveness of selectedU.S. agricultural export commodities / J.M. Kagochi, C.M. Jolly // InternationalJournal of Applied Economics. – 2010. – № 7(1). – P. 58-77.168. Kalotra,A.Marketingstrategiesofdifferentpharmaceuticalcompanies[Электронный ресурс] / A.
Kalotra // Journal of Drug Delivery & Therapeutics.– 2014. – № 4(2). – P. 64-71. – Режим доступа: http://jddtonline.info/index.php/jddt/article/view/771 (дата обращения: 14.09.2016).169. Ketels, C. Recent Research on Competitiveness and Clusters: What Are theImplications for Regional Policy? / C. Ketels // Cambridge Journal of Regions.Economy and Society. – 2013. – № 6(2). – P.
269-284.189170. Koenig, P. Local export spillovers in France / P. Koenig, F. Mayneris, S. Poncet //European Economic Review. – 2010. – № 54. – P. 622-641.171. Kussainov, A. Kazakhstan: Common pharmaceutical market of the Eurasian economicunion: rules of access and competition [Электронный ресурс] / A.
Kussainov,I. Yuldasheva // Kazakhstan business updates. – 2015. – Режим доступа:http://www.dentons.com/en/insights/guides-reports-and-whitepapers/2015/december/7/kazakhstan-business-updates (дата обращения: 14.10.2016).172. Kyrgyzstan Pharmaceutical Country Profile [Электронный ресурс] // World HealthOrganisation.–2013./areas/coordination/–Режимдоступа:http://www.who.int/medicinesLowResPharmaceutical_Country_Profile_Kyrgyz_Republic.pdf(дата обращения: 14.10.2016).173. Lawless, M.
Marginal distance: Does export experience reduce firm trade costs? /M. Lawless // Open Economies Review. – 2013. – № 24. – P. 819-841.174. Life Sciences Cluster Report [Электронный ресурс] // Jones Lang LaSalle. – 2014.– Режим доступа: https://www.jll.com/Research/2014-global-life-sciences-reportJLL.pdf?654be919-aef1-45a0-bef3-ab01d0a4ece6 (дата обращения: 14.10.2016).175. Life Sciences Outlook [Электронный ресурс] // Jones Lang LaSalle. – 2015.–Режимдоступа:http://www.us.jll.com/united-states/en-us/Documents/Life-Sciences/JLL-US-Life-Science-Outlook-2015.pdf (дата обращения: 11.10.2016).176. Life Sciences Outlook [Электронный ресурс] // Jones Lang LaSalle. – 2016.– Режим доступа: http://www.us.jll.com/united-states/en-us/research/7427/us-lifesciences-outlook-2016-jll (дата обращения: 11.10.2016).177. Life Sciences Outlook 2016 [Электронный ресурс] // Clarkston Consulting.
– 2016.– Режим доступа: http://clarkstonconsulting.com/wp-content/uploads/2016/01/LifeSciences-Outlook_2016.pdf (дата обращения: 11.10.2016).178. Life Sciences Report 2015 – Healthcare Industries in Berlin-Brandenburg[Электронныйресурс]//HealthCapital.–2015.–Режимдоступа:https://www.berlin-partner.de/fileadmin/user_upload/01_chefredaktion/02_pdf/publikationen/Life-Sciences-Report_en.pdf (дата обращения: 11.10.2016).179. Malmberg, A.
Agglomeration and Firm Performance: Economies of Scale,Localisation, and Urbanisation among Swedish Export Firms / A. Malmberg,B. Malmberg, P. Lundquist // Environment and Planning. – 2000. – № 32(2).– P. 305-321.190180. Mayer, T. The happy few: the internationalisation of European firms: new facts basedon firm-level evidence [Электронный ресурс] / T. Mayer, G.M. Ottaviano // Bruegelblueprintseries.–2007.–Volume3.–95–P.Режимдоступа:http://aei.pitt.edu/8353/1/blueprint3_EFIM.pdf (дата обращения: 19.10.2016).181.
Melitz, M.J. The impact of trade on intra-industry reallocations and aggregate industryproductivity / M.J. Melitz // Econometrica. – 2003. – Volume 71. – № 6.– P. 1695-1725.182. Nalimov, P.A. Big Pharma: Trick or Treat for Global Health / P.A. Nalimov,D.Y. Rudenko, D.F. Skripnuk // Mediterranean Journal of Social Sciences. – 2015.– Volume 6. – № 1. – P.
216-223.183. National strategy and plan of action for pharmaceutical manufacturing development inEthiopia (2015–2025). Developing the pharmaceutical industry and improving access[Электронный ресурс] // Federal Democratic Republic of Ethiopia: Ministry ofHealthandMinistryofIndustry.http://www.who.int/phi/publications/Ethiopia_–2015.–Режимдоступа:strategy_local_poduction.pdf(датаобращения: 19.10.2016).184.
Naude, W. Do export costs matter in determining whether, when, and how muchAfrican firms export? [Электронный ресурс] / W. Naude, M. Matthee // JICAResearch Institute. – 2012. – № 38. – P. 1-42 – Режим доступа: http://repository.ri.jica.go.jp/dspace/bitstream/10685/93/1/JICA-RI_WP_No.38_2012_2.pdf(датаобращения: 23.10.2016).185. New Jersey’s Life Sciences Industry Cluster [Электронный ресурс] // New JerseyDepartment of Labor & Workforce Development Office of Research & Information.– 2016. – Режим доступа: http://lwd.state.nj.us/labor/lpa/pub/empecon/biopharma.pdf(дата обращения: 23.10.2016).186.
Noji, T. Life Sciences and Biotechnology Industry Clusters in Europe - BuildingBridges between Science and Industry [Электронный ресурс] / T. Noji, Y. Omiya //Mizuho Corporate Bank (Mizuho Industry Focus). – 2013. – Режим доступа:https://www.mizuhobank.com/fin_info/industry/pdf/mif_122.pdf (дата обращения:23.10.2016).187. Oviatt, B.M. Global start-ups: Entrepreneurs on a worldwide stage / B.M. Oviatt,P.P. McDougall // Academy of Management Executive. – 1995.
– Volume 9. – № 2.– P. 30-43.191188. Pharma 2020: Challenging business models. Which path will you take?[Электронный ресурс] // PricewaterhouseCoopers. – 2016. – Режим доступа:http://www.pwc.com/gx/en/industries/pharmaceuticals-life-sciences/pharma2020/business-models.html (дата обращения: 06.10.2016).189. Pharma 2020: Supplying the future. Which path will you take? (Pharmaceuticals andLife Sciences) [Электронный ресурс] // PricewaterhouseCoopers. – 2015. – Режимдоступа: https://www.pwc.de/de/gesundheitswesen-und-pharma/assets/pharma_2020_sc_final.pdf (дата обращения: 06.10.2016).190.
Pharma emerging markets 2.0: How emerging markets are driving the transformationof the pharmaceutical industry [Электронный ресурс] // Booz & Company PricewaterhouseCoopers. – 2014. – Режим доступа: http://www.strategyand.pwc.com/reports/pharma-emerging-markets (дата обращения: 09.10.2016).191. Pharmaceutical Guide: Armenia 2014 [Электронный ресурс] // EnterpriseDevelopment & Market Competitiveness Project. – 2014. – Режим доступа:(датаhttp://mineconomy.am/uploades/Pharmaceutical_-2014.pdfобращения:09.10.2016).192.
Pharmaceutical Market Overview (Yerevan) [Электронный ресурс] // AvenueConsulting Group. – 2014. – Режим доступа: http://www.avenueconsulting.am/resources/avenue//uploads/pdf/9f80c01ce0c6f81f5fd447aea7d41b2b.pdf(датаобращения: 10.10.2016).193. Pharmerging Markets: Picking a pathway to success [Электронный ресурс] //IMSHealth.–2014.–Режимдоступа:https://www.imshealth.com/files/web/Global/Services/Services%20TL/IMS_Pharmerging_WP.pdf(датаобращения: 10.10.2016).194. Research and development in the pharmaceutical sector, in Health at a Glance 2015:OECD Indicators [Электронный ресурс] // OECD Publishing, Paris. – 2015.–Режимдоступа:http://dx.doi.org/10.1787/health_glance-2015-70-en(датаобращения: 10.10.2016).195.
Revitalizing Africa’s pharmaceutical industry [Электронный ресурс] // Abidjan:AfricanDevelopmentBankGroup.–2014.–Режимдоступа:http://allafrica.com/stories/201406041633.html (дата обращения: 10.10.2016).196. Sadat, T. Shifting paths of pharmaceutical innovation: Implications for the globalpharmaceutical industry / T.
Sadat, R. Russell, M. Stewart // International Journal ofKnowledge, Innovation and Entrepreneurship. – 2014. – Volume 2. – № 1. – P. 6-31.192197. Söderlund, B. Dynamic effects of institutions on firm-level exports / B. Söderlund,P.G. Tingvall // Review of World Economics. – 2014. – Volume 150. – Issue 2.– P. 277-308.198. Sutton, J. Quality, trade and the moving window: The globalization process / J.
Sutton// The Economic Journal. – 2007. – № 117(524). – P. 469-498.199. Svejnar, J. Do institutions, ownership and competition explain firm performance?Evidence from 26 Transition Countries [Электронный ресурс] / J. Svejnar,S.J. Commander // IZA Discussion Paper. – 2007. – № 2637. – 55 P.
– Режимдоступа: http://repec.iza.org/dp2637.pdf (дата обращения: 10.10.2016).200. Syverson, C. What determines productivity? / C. Syverson // Journal of EconomicLiterature. – 2011. – Volume 49. – № 2. – P. 236-365.201. The Belgian pharmaceutical cluster [Электронный ресурс] // Institute for Strategyand Competitiveness. Harvard Business School. – 2011. – Режим доступа:http://www.isc.hbs.edu/resources/courses/moc-course-at-harvard/documents/pdf/student-projects/belgium_pharmaceuticals_2011.pdf (дата обращения: 07.10.2016).202. The Biopharmaceutical Research and Development Enterprise: Growth platform foreconomies around the world [Электронный ресурс] // PhRMA.
– 2012. – Режимдоступа:http://www.phrma.org/sites/default/files/pdf/phrma_growthplatformforeconomiesaroundthe world_20120508.pdf (дата обращения: 07.10.2016).203. The economic footprint of the pharmaceutical industry: Regional breakdown anddifferentiation between originators and generics [Электронный ресурс] // IFPMA.– 2015.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
